In the second scenario, lung cancer patients undergoing surgical procedures received VGT-309, a cathepsin-targeting indocyanine green (ICG) agent designed to illuminate the tumor microenvironment through fluorescence in areas with heightened cathepsin activity. The gene discussed is CTSS; the disease is neoplasm.